State of Parkinson's Research, August 2026

A dated, reproducible monthly snapshot of the Parkinson's clinical trial landscape, archived 2026-08-01 so the figures stay citable over time.

Headline Figures

• Recruiting trials tracked: 507
• New this month: 0
• Phase 3 trials: 12
• Countries with trial sites: 42
• Interventional: 355
• Observational: 152
• Average minimum age: 31 years
• Total ever opened (lifetime, survivorship-immune): 0

Month-over-Month Movement vs July 2026

• Recruiting trials: 507 vs 502 last month, up 5 (+1%)
• Phase 3 trials: 12 vs 11 last month, up 1 (+9%)
• Countries with trials: 42 vs 43 last month, down 1 (-2%)
• Interventional trials: 355 vs 354 last month, up 1 (+0%)

Takeaways

• As of August 2026, 507 Parkinson's trials are recruiting across 42 countries.
• That's up 5 from July 2026 (+1%).
• The most common research focus among recruiting trials is Alpha-synuclein (3 trials).

Top Countries

• United States: 167 recruiting trials
• China: 65 recruiting trials
• Italy: 41 recruiting trials
• Turkey: 37 recruiting trials
• France: 28 recruiting trials
• United Kingdom: 28 recruiting trials
• Germany: 26 recruiting trials
• Canada: 25 recruiting trials
• Netherlands: 16 recruiting trials
• Spain: 16 recruiting trials

Top Drug Classes

• alpha-syn: 3 trials
• DBS: 2 trials
• monoclonal-antibody: 2 trials
• GBA: 1 trials
• focused-ultrasound: 1 trials
• gene-therapy: 1 trials

Top Sponsors

• University of Minnesota: 10 trials
• VA Office of Research and Development: 9 trials
• Xiangya Hospital of Central South University: 7 trials
• Medical University of South Carolina: 6 trials
• University of Alabama at Birmingham: 6 trials
• University of Exeter: 5 trials
• Radboud University Medical Center: 5 trials
• Beijing Tiantan Hospital: 5 trials
• Michael J. Fox Foundation for Parkinson's Research: 5 trials
• AbbVie: 5 trials

See the live State of Parkinson's Research dashboard for the current interactive picture.